

# Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-onset Still's Disease

**Seoung Wan Nam**

Wonju Severance Christian Hospital

**SuMan Kang**

Hanyang University Hospital for Rheumatic Diseases

**Jun Hyeok Lee**

Yonsei University Wonju College of Medicine

**Dae Hyun Yoo** (✉ [dhyoo@hanyang.ac.kr](mailto:dhyoo@hanyang.ac.kr))

Hanyang University Hospital for Rheumatic Diseases

---

## Research article

**Keywords:** Interleukin-37, Interleukin-18, Adult-onset Still's disease

**Posted Date:** January 19th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-147805/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

**Backgrounds/Aims:** The aim of this study was to evaluate the usefulness of serum interleukin (IL)-37 and IL-18 as disease activity markers of adult-onset Still's disease (AOSD) and to compare their related clinical features.

**Methods:** Forty-five patients with a set of high and subsequent low disease activity status of AOSD that fall within a 12-month period were enrolled. Modified Pouchot (mPouchot) score and serologic disease activity markers including serum levels of IL-37 and IL-18 were compared between high and low disease activity status. The relationships between disease activity parameters and differences in serum levels of IL-37 and IL-18 according to the presence of each disease manifestation of AOSD were evaluated in high disease activity status.

**Results:** mPouchot score and all serologic disease activity markers including ESR, CRP, ferritin, IL-37, and IL-18 significantly declined in low disease activity status ( $p < 0.01$ ). Though both serologic cytokines positively correlated with mPouchot score, the two did not correlate with each other in high disease activity status. IL-18 positively correlated with ferritin, AST, and LDH ( $p < 0.05$ ). In contrast, IL-37 correlated better with CRP ( $p < 0.01$ ). The expression level of IL-37 and presence of leukocytosis were closely related. However, the expression level of IL-18 was closely related to presence of pleuritis, pneumonitis, abnormal LFT, and hyperferritinemia.

**Conclusions:** Both IL-37 and IL-18 can be useful serologic markers of AOSD activity, but their pathologic roles in disease activity might be different.

## Introduction

Adult-onset Still's disease (AOSD) is a rare systemic auto-inflammatory disorder characterized by four cardinal symptoms of spiking fever, arthralgia or arthritis, evanescent salmon-colored rash, and leukocytosis with neutrophil predominance [1, 2]. The diagnosis of AOSD is still challenging owing to its heterogeneous clinical manifestations and few disease specific markers [3]. Likewise, it is difficult to assess disease activity of AOSD. Pouchot et al. described a systemic disease activity score comprised of 12 main signs and symptoms of AOSD; this scoring system was later modified by Rau et al. [4, 5]. Several biomarkers were proposed as potential disease activity parameters of AOSD including C-reactive protein (CRP), ferritin, and interleukin (IL)-18 [1]. However, no reliable disease activity parameter exists yet [6]. Given the potential polycyclic evolution of AOSD, it is necessary to identify biomarkers for accurate assessment of disease activity to improve AOSD management [1].

Although the pathogenesis of AOSD is unclear, many proinflammatory cytokines, such as IL-1 $\beta$ , IL-6, tumor necrosis factor (TNF)- $\alpha$ , interferon (IFN)- $\gamma$ , and IL-18, seem to be involved; levels of these cytokines positively correlated with disease activity [6]. Among these cytokines, IL-18 is the most promising biomarker of AOSD as its serum level is particularly high in AOSD compared to other inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, and sepsis [1, 3, 7]. IL-18 has not only been suggested as a potential biomarker for differential diagnosis of AOSD, but also for evaluation of disease activity [1, 3]. However, its use in routine investigations has not been widely accepted as evidence of its reliability is insufficient [1, 6, 8].

IL-37 is a newly discovered member of the IL-1 cytokine family and has been identified as an inhibitor of immune responses in contrast to IL-18, another member of the IL-1 family [9]. Studies have shown elevated expression of IL-37 in patients with autoimmune diseases such as RA, systemic lupus erythematosus (SLE), AS, psoriasis, systemic juvenile idiopathic arthritis, and Graves' disease. Also, plasma level of IL-37 positively correlated with the

disease activity parameters in patients with RA, SLE, AS, and systemic juvenile idiopathic arthritis [9–14]. A recent study identified increased expression of IL-37 and its positive correlation with disease activity markers in patients with AOSD [15]. However, our knowledge about the role of IL-37 in the pathogenesis of AOSD and its clinical applicability as a biomarker of the disease is very limited. Moreover, no study has compared IL-37 and IL-18 as disease activity parameters in patients with AOSD.

In this study, we evaluated how serum levels of IL-37 and IL-18 reflect the activity of AOSD using paired serum samples of high and low disease activity status in a cohort of patients with AOSD.

## Methods

### Study population and the evaluation period

Sixty patients with AOSD were enrolled in this study, all of whom met the criteria of Yamaguchi et al. [16]. Those with concurrent infection, malignancies, or other rheumatic diseases were not eligible. The medical records of patients were reviewed thoroughly regarding AOSD activity status assessed by the modified Pouchot (mPouchot) score proposed by Rau et al. [5, 7]. The total score that ranges from 0 to 12 is calculated by assigning 1 point to each of these items: presence of fever, evanescent rash, sore throat, arthritis, myalgia, pleuritis, pericarditis, pneumonitis, lymphadenopathy, hepatomegaly or abnormal liver function tests, white blood cell count (WBC) > 15,000/mm<sup>3</sup>, and serum ferritin > 3,000 ng/mL. Consistent with previous studies, high disease activity status of AOSD was defined as mPouchot score  $\geq 4$  [5, 7]. Low disease activity status of AOSD was defined arbitrarily as mPouchot score  $\leq 2$  [17]. A set of high and subsequent low disease activity status that fall within a 12-month period were determined in each patient. For comparison of clinical parameters between high and low disease activity status of AOSD, patients without a record of definite high disease activity status or those with a high and low disease activity status interval longer than 12 months were excluded from the study.

A retrospective analysis of AOSD patients who prospectively visited a single university hospital for periodic examination or admission between August 2016 and April 2017 was performed. This analysis was an evaluation of clinical information from initial diagnosis of AOSD until the time of investigation, April 2017. The study protocol was approved by the Institutional Review Board of Hanyang University Hospital, and informed consent was received from all participants (IRB no. HYUH 2016-06-007).

### Laboratory studies

Serial serum samples were collected from all study patients at 1- to 3-month intervals depending on the clinical situation. In addition to routine clinical laboratory studies including complete blood cell count and liver function tests, disease activity parameters such as ferritin, IL-18, and IL-37 levels were measured. Serum samples were obtained in the morning after overnight fasting, and care was taken to avoid hemolysis. For measurement of cytokines, samples were centrifuged at 2500 rpm for 15 min at 5 °C within 30 min of collection at room temperature and maintained at -70 °C until use [3].

### Statistical analysis

Data are expressed according to the properties of the variables. The mPouchot score, clinical parameters included in the mPouchot score, and laboratory parameters were compared between high and low disease activity status using the McNemar test, Exact McNemar test, or Wilcoxon signed-rank test, as appropriate.

Clinical characteristics and laboratory parameters were analyzed in high disease activity status of AOSD. The relationships among the disease activity parameters were evaluated using Spearman's correlation coefficients. The patients were divided into two groups, the IL-37 dominant group (patients with IL-37  $\geq$  median and IL-18 < median) and the IL-18 dominant group (patients with IL-18  $\geq$  median and IL-37 < median); and clinical characteristics and laboratory parameters were compared using Wilcoxon rank-sum test and Fisher's exact test, as appropriate. Serum levels of IL-37 and IL-18 were compared according to the presence or absence of each disease manifestation of AOSD by the Wilcoxon rank-sum test.

All statistical analyses were performed using SAS software version 9.4 and R version 3.5.3.

## Results

Among the 60 patients recruited for this study, 45 were included. Nine patients did not show definite high disease activity defined as mPouchot score  $\geq$  4, and six patients did not cycle between high and low disease activity status within a 12-month period; these 15 were excluded from the study.

## Demographic and clinical characteristics

The demographic and clinical characteristics of patients with AOSD included in this study are shown in Table 1. The overall mean age of the patients was 47.1 ( $\pm$  14.0) years, with a mean disease duration of 59.5 ( $\pm$  48.2) months; female patients were more prevalent (86.7%). Retrospective analyses of the medical records of all patients revealed that the most common AOSD onset symptom was a combined pattern of systemic and articular diseases (68.9%). 57.8% of patients showed two or more systemic disease flare-ups by April 2017, the end of the observation period.

Table 1

Demographic and clinical characteristics of patients with adult-onset Still's disease<sup>a</sup>

	Total patients (n, 45)
Age	47.1 ± 14.0
Female, n (%)	39 (86.7)
Disease duration (months)	59.5 ± 48.2
Number of Yamaguchi criteria met at diagnosis	6.3 ± 1.0
AOSD onset symptom, n (%)	
Systemic	11 (24.4)
Articular	3 (6.7)
Combined	31 (68.9)
Number of disease flares (per year)	0.6 ± 0.4
Disease duration until high disease activity status (months)	28.9 ± 43.3
Interval between high and low disease activity status (months)	6.0 ± 2.7
Medications used during the evaluation period, n (%)	
Corticosteroids	45 (100)
Cumulative corticosteroid dose (mg) <sup>b</sup>	2769.7 ± 1511.0
Mean corticosteroid dose (mg/day) <sup>b</sup>	17.1 ± 9.5
Corticosteroid pulse therapy <sup>c</sup>	8 (17.8)
Methotrexate	35 (77.8)
Leflunomide	10 (22.2)
Cyclosporin A	18 (40.0)
Azathioprine	2 (4.4)
Hydroxychloroquine	5 (11.1)
IV immunoglobulin	1 (2.2)
Tocilizumab	3 (6.7)

AOSD adult-onset Still's disease, IV intravenous.

<sup>a</sup> Values are shown as mean ± standard deviation unless otherwise indicated.

<sup>b</sup> Values represent mg of prednisone equivalent and do not include the dose of corticosteroid pulse therapy.

<sup>c</sup> Corticosteroid pulse therapy is defined as administration of ≥ 250 mg prednisone equivalent per day for one or a few days.

	Total patients (n, 45)
Patients with re-flare after low disease activity status	
Re-flare within 1 year (missing = 3), n (%)	14 (33.3)
Duration until re-flare (months)	4.3 ± 4.8
Re-flare within 2 years (missing = 10), n (%)	19 (54.3)
Duration until re-flare (months)	8.3 ± 7.5
Death, n (%)	1 (2.2)
<i>AOSD</i> adult-onset Still's disease, <i>IV</i> intravenous.	
<sup>a</sup> Values are shown as mean ± standard deviation unless otherwise indicated.	
<sup>b</sup> Values represent mg of prednisone equivalent and do not include the dose of corticosteroid pulse therapy.	
<sup>c</sup> Corticosteroid pulse therapy is defined as administration of ≥ 250 mg prednisone equivalent per day for one or a few days.	

The mean interval between high disease activity status and subsequent low disease activity status was 6.0 (± 2.7) months. During this period, 17.8% of patients underwent steroid pulse therapy, and the most frequently used immune modulating medications were methotrexate (77.8%), cyclosporin A (40.0%), and leflunomide (22.2%). Approximately one-third of patients (33.3%) had a re-flare of AOSD within one year after low disease activity status, with a mean duration until re-flare of 4.3 (± 4.8) months. More than one-half of patients (54.3%) had a re-flare within two years after achieving low disease activity status.

## Paired comparison of clinical features and laboratory parameters between high and low disease activity status

As shown in Table 2, mPouchot score and all the laboratory parameters investigated, including IL-37 and IL-18, were significantly lower in the subsequent low disease activity status compared to the high disease activity status. The most common disease manifestation of AOSD in high disease activity status were fever (86.7%), skin rash (82.2%), arthritis (73.3%), myalgia (68.9%), and sore throat (66.7%). The least frequent clinical findings were pleuritis (13.3%) and pericarditis (4.4%), which failed to show significant difference between high and low disease activity states.

Table 2

Paired comparison of clinical characteristics between high and low disease activity status in patients with adult-onset Still's disease<sup>a</sup>

	High disease activity (mPouchot score $\geq 4$ )	Low disease activity (mPouchot score $\leq 2$ )	p
Modified Pouchot score <sup>b</sup>	6.0 (4.5–7.0)	0 (0–0)	< 0.01
Fever	39 (86.7)	0 (0)	< 0.01
Evanescient rash	37 (82.2)	2 (4.4)	< 0.01
Sore throat	30 (66.7)	0 (0)	< 0.01
Arthritis	33 (73.3)	5 (11.1)	< 0.01
Myalgia	31 (68.9)	0 (0)	< 0.01
Pleuritis	6 (13.3)	0 (0)	0.03
Pericarditis	2 (4.4)	1 (2.2)	0.32
Pneumonitis	12 (26.7)	0 (0)	< 0.01
Lymphadenopathy	14 (31.1)	0 (0)	< 0.01
Hepatomegaly or abnormal LFT <sup>c</sup>			
Hepatomegaly	4 (8.9)	0 (0)	0.13
Abnormal LFT <sup>c</sup>	29 (64.4)	3 (6.7)	< 0.01
WBC > 15,000 ( $10^9/L$ )	19 (42.2)	2 (4.4)	< 0.01
Ferritin > 3,000 (ng/mL)	22 (48.9)	0 (0)	< 0.01
Laboratory findings <sup>b</sup>			
WBC ( $10^9/L$ )	12.8 (7.4–20.0)	8.0 (6.9–10.1)	< 0.01
ESR (mm/hr)	79.5 (34.0–101.0)	13.0 (8.0–32.0)	< 0.01
CRP (mg/dL)	7.5 (3.2–12.7)	0.4 (0.2–0.4)	< 0.01
AST (U/L)	38.0 (26.0–56.0)	20.0 (16.0–23.0)	< 0.01
ALT (U/L)	32.0 (17.0–56.0)	16.0 (12.0–19.5)	< 0.01

*mPouchot* modified Pouchot, *LFT* liver function test, *WBC* white blood cells, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *LDH* lactate dehydrogenase, *IL* interleukin.

<sup>a</sup> Values are number (percentage) unless otherwise indicated.

<sup>b</sup> Median (Q1-Q3)

<sup>c</sup> Defined as abnormal value of AST, ALT, or alkaline phosphatase

	High disease activity (mPouchot score $\geq$ 4)	Low disease activity (mPouchot score $\leq$ 2)	p
LDH (U/L)	368.0 (285.0–489.0)	198.0 (161.0–240.0)	< 0.01
Ferritin (ng/mL)	2628.0 (538.4–8791.0)	59.3 (35.4–108.1)	< 0.01
IL-18 (pg/mL)	92874.2 (49764.2–141944.5)	1316.0 (666.8–6069.9)	< 0.01
IL-37 (pg/mL)	231.6 (86.5–754.0)	29.2 (7.5–64.0)	< 0.01
<i>mPouchot</i> modified Pouchot, <i>LFT</i> liver function test, <i>WBC</i> white blood cells, <i>ESR</i> erythrocyte sedimentation rate, <i>CRP</i> C-reactive protein, <i>AST</i> aspartate aminotransferase, <i>ALT</i> alanine aminotransferase, <i>LDH</i> lactate dehydrogenase, <i>IL</i> interleukin.			
<sup>a</sup> Values are number (percentage) unless otherwise indicated.			
<sup>b</sup> Median (Q1-Q3)			
<sup>c</sup> Defined as abnormal value of AST, ALT, or alkaline phosphatase			

## Correlations between disease activity parameters in high disease activity status

As shown in Table 3, IL-37 and IL-18 showed different patterns of correlations with other serologic disease activity markers in high disease activity status of AOSD. Unlike IL-18, which correlated better with serum levels of ferritin, lactate dehydrogenase (LDH), and aspartate aminotransferase (AST), IL-37 correlated better with CRP. IL-37 and IL-18 showed comparable correlations with systemic disease activity score (mPouchot score) (Spearman's rho = 0.355 and 0.399, respectively,  $p < 0.05$ ). However, no association was established between IL-37 and IL-18.

Table 3

Correlation between disease activity parameters in high disease activity status of adult-onset Still's disease

	mPouchot score	ESR	CRP	ferritin	AST	ALT	LDH	IL-18	IL-37
mPouchot score	1	0.515**	0.481**	0.616**	0.247	0.228	0.236	0.399**	0.355*
ESR	0.515**	1	0.418**	0.218	-0.140	-0.04	-0.340*	-0.126	0.270
CRP	0.481**	0.418**	1	0.424**	0.09	-0.09	0.079	0.287	0.573**
ferritin	0.616**	0.218	0.424**	1	0.543**	0.343*	0.564**	0.656**	0.336*
AST	0.247	-0.140	0.090	0.543*	1	0.559**	0.640**	0.468*	0.026
ALT	0.228	-0.040	-0.087	0.343*	0.559**	1	0.263	0.238	-0.088
LDH	0.236	-0.340*	0.079	0.564**	0.640**	0.263	1	0.741**	0.153
IL-18	0.399**	-0.126	0.287	0.656**	0.468**	0.238	0.741**	1	0.159
IL-37	0.355*	0.270	0.573**	0.336*	0.03	-0.088	0.153	0.159	1

By Spearman's correlation coefficients. \* Correlation is significant at the 0.05 level. \*\* Correlation is significant at the 0.01 level.

*mPouchot* modified Pouchot, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *LDH* lactate dehydrogenase, *IL* interleukin.

## IL-37 and IL-18 in high disease activity status of AOSD

As shown in Fig. 1, serum IL-37 and IL-18 levels were diffusely scattered at high disease activity status of AOSD, showing no linear correlation. Clinical characteristics were compared between two groups, each with 10 patients, with contrasting serum concentration levels of IL-37 and IL-18 (Additional file 1: Table S1). There were no significant differences between the IL-37 dominant group and the IL-18 dominant group in demographics, AOSD disease course, incidence of disease flares, use of immune modulating drugs, and re-flare rate after low disease activity status. However, IL-18 dominant group showed higher LDH level at high disease activity status, and these patients required higher mean steroid dose for achieving low disease activity status ( $p < 0.01$ , respectively). In addition, these patients required longer treatment periods until achieving low disease activity status compared to patients in the IL-37 dominant group with borderline significance (median of 8 months in the IL-18 dominant group vs. 4 months in the IL-37 dominant group,  $p = 0.06$ ). However, there was no difference in mPouchot score between the two groups in high disease activity status.

As shown in Table 4, IL-37 and IL-18 serum levels showed different patterns of increase according to the presence of each disease manifestation of AOSD at high disease activity status. Serum IL-18 levels was higher in patients with pleuritis, pneumonitis, abnormal liver function test, and hyperferritinemia ( $p < 0.05$ ). In contrast, serum IL-37 level was only higher in patients with leukocytosis ( $p < 0.01$ ). There was no concurrent increase in serum levels of IL-37 and IL-18 related to presence of any clinical domain of AOSD.

Table 4

Comparison of serum IL-37 and IL-18 levels according to disease manifestations at high disease activity status of patients with adult-onset Still's disease<sup>a</sup>

Disease manifestation	N	Serum IL-37 level	p	Serum IL-18 level	p
Fever	(+), n = 39	320.6 (87.1–794.9)	0.09	95879.0 (51460.0–168103.9)	0.14
	(-), n = 6	88.3 (24.4–150.0)		46295.9 (22779.3–86407.4)	
Skin rash	(+), n = 37	231.6 (94.5–740.1)	0.58	90140.0 (39970.0–131420.0)	0.14
	(-), n = 8	339.3 (30.2–857.2)		143178.8 (72357.1–342925.0)	
Sore throat	(+), n = 30	434.4 (97.1–794.9)	0.10	88979.8 (32665.4–131420.0)	0.14
	(-), n = 15	114.4 (47.7–365.2)		95879.0 (76861.7–203430.2)	
Arthritis	(+), n = 33	185.0 (86.5–740.1)	0.34	90140.0 (39970.0–131420.0)	0.15
	(-), n = 12	409.4 (99.0–2383.6)		116849.2 (57839.5–232115.6)	
Myalgia	(+), n = 31	157.4 (82.5–740.1)	0.53	80626.0 (32665.4–141081.1)	0.40
	(-), n = 14	409.4 (86.5–794.9)		94815.6 (86407.3–184044.8)	
Pleuritis	(+), n = 6	444.7 (64.3–5160.0)	0.73	154595.5 (131385.5–203430.2)	0.02
	(-), n = 39	231.6 (86.5–740.1)		86407.3 (32665.4–131420.0)	
Pericarditis	(+), n = 2	532.1 (64.3–1000.0)	0.89	150216.7 (97003.2–203430.2)	0.26
	(-), n = 43	231.6 (86.5–754.0)		91552.2 (39970.0–141944.5)	
Pneumonitis	(+), n = 12	504.2 (172.6–978.6)	0.17	116849.2 (88691.5–184742.5)	0.045
	(-), n = 33	150.0 (85.5–716.0)		86407.3 (26677.0–131420.0)	
Lymphadenopathy	(+), n = 14	409.4 (157.4–794.9)	0.14	131402.8 (78019.7–168103.9)	0.12
	(-), n = 31	137.7 (64.3–740.1)		86407.3 (32665.4–102312.8)	
Hepatomegaly	(+), n = 4	458.4 (170.8–776.6)	0.89	93422.0 (85447.0–874084.9)	0.49
	(-), n = 41	185.0 (86.5–754.0)		91552.2 (39970.0–141944.5)	

IL interleukin, LFT liver function test, WBC white blood cells.

<sup>a</sup> Values are median (Q1-Q3).

Disease manifestation	N	Serum IL-37 level	p	Serum IL-18 level	p
Abnormal LFT	(+), n = 29	231.6 (85.5–740.1)	0.86	97003.2 (65914.8–168103.9)	0.03
	(-), n = 16	239.0 (90.5–755.6)		67616.7 (22186.5–97900.1)	
WBC > 15,000 (10 <sup>9</sup> /L)	(+), n = 19	716.0 (231.6–972.9)	< 0.01	97003.2 (51840.0–168103.9)	0.36
	(-), n = 26	123.5 (64.3–320.6)		82213.5 (26677.0–141081.1)	
Ferritin > 3,000 (ng/mL)	(+), n = 22	656.1 (82.5–957.1)	0.18	154592.5 (96757.0–203430.2)	< 0.01
	(-), n = 23	150.0 (87.1–453.5)		58371.8 (22779.3–90140.0)	
<i>IL</i> interleukin, <i>LFT</i> liver function test, <i>WBC</i> white blood cells.					
<sup>a</sup> Values are median (Q1-Q3).					

## Discussion

AOSD is a systemic auto-inflammatory disorder that presents with heterogeneous clinical manifestations. Its pathogenesis is largely unknown, and no single efficient disease activity marker for this disease has been identified [1, 3]. Regarding its heterogeneity in the clinical presentation, we might need multi-modal approaches for investigating pathogenic mechanisms and assessing disease activity. In this study, we demonstrated that IL-37 level reflects disease activity of AOSD, as does the known cytokine biomarker IL-18, but in different ways [1].

IL-37 and IL-18 comprise the IL-18 subfamily of the IL-1 family as both bind to the IL-18 receptor [18]. IL-18 plays a key role in the polarized type 1 innate and adaptive responses that can possibly extend to mediation of autoimmune diseases [19]. In contrast, IL-37 is known to be negatively involved in development and pathogenesis of autoimmune diseases [8, 9, 20, 21]. Many studies have revealed the protective anti-inflammatory roles of IL-37, including an inhibitory effect on the activity of IL-18 [20]. Previous studies supported the usefulness of IL-18 in AOSD differential diagnosis, disease activity evaluation, subset prediction (systemic or chronic articular subtypes), and severity assessment [1, 3, 7, 17, 22, 23]. However, there is scarce information about the role of IL-37 in AOSD [8]. Serum level of IL-18 was higher in patients with active AOSD compared to healthy controls, patients with other inflammatory diseases, or patients with inactive AOSD, suggesting IL-18 as a disease activity marker of AOSD [3, 7, 17, 22–25]. Chi et al. recently reported that the serum level of IL-37 was higher in patients with AOSD compared to healthy subjects, and significant difference in serum level of IL-37 was observed between patients with active and inactive disease status. The serum level of IL-37 was even higher in patients with inactive disease compared to healthy subjects. In addition, their results showed a significant decrease in serum level of IL-37 after treatment in 10 patients with serial work-up data [8]. Though previous studies suggested both IL-37 and IL-18 as estimators of disease activity in patients with AOSD, controversies exist as to whether IL-18 could serve as a marker for disease remission and follow-up [1]. We noted four studies that demonstrated changes in serum level of IL-18 between high and subsequent low disease activity status after treatment [3, 17, 26, 27]. Two studies from the same institution showed no significant decrease in serum IL-18 level after treatment in 16 and 17 patients with AOSD, respectively [17, 26]. However, they did not apply specific criteria for high disease activity status of AOSD.

Contrary to their results, our previous study indicated that serum IL-18 declined significantly in 18 patients with AOSD who responded to therapy but not in non-responders [3]. In addition, the serum IL-18 level was higher in patients with low disease activity compared to those in remission unlike other serologic disease activity markers. Therefore, we previously suggested IL-18 as an efficient marker for remission and follow-up in patients with AOSD [3]. In the current study, serum IL-18 level decreased significantly in patients who achieved low disease activity status along with other disease activity markers including leukocytes, ESR, CRP, AST, alanine aminotransferase (ALT), ferritin, and IL-37 (Table 2). Our results are also compatible with those of another report of 11 patients with AOSD [27]. The differing results regarding change of serum IL-18 level could be due to different criteria for high and low disease activity status or differences in baseline characteristics of study populations, such as disease subset type. Previous studies have demonstrated that serum IL-18 level tends to be higher in patients presenting with systemic subset compared to chronic articular subtype [1, 28]. After applying clear set criteria for both high and low disease activity status, we noted that both IL-37 and IL-18 could be used as disease activity evaluators even for follow-up of AOSD activity.

We evaluated IL-37 and IL-18 in relation to other disease activity parameters and various clinical features in high disease activity status of AOSD to compare their roles in the activity of this disease. In addition to there being no correlation between IL-18 and IL-37 serum levels, the differences in their patterns of positive correlations with other serologic markers suggest their different pathogenic roles in disease activity. In addition, there were different patterns in the increase of both serum cytokines regarding the presence of each clinical manifestation of AOSD. IL-37 seems to be more related with non-specific markers of inflammation like CRP and leukocytes [1]. In contrast, IL-18 seems to be more related with pleuritis, pneumonitis, and serologic markers associated with liver injury such as AST, ALT, ferritin, and LDH [22, 25, 29–31]. Macrophage-derived IL-18 plays a fundamental role in hepatocyte apoptosis via activation of the Fas/Fas ligand pathway [19, 29, 32] Priori et al. demonstrated that the serum IL-18 level is markedly increased in patients with AOSD-related hepatitis. In addition, they histologically revealed that IL-18 was highly expressed by activated CD68 + liver macrophages and Kupffer cells in a patient with AOSD [25]. It has been known that hyperferritinemia in AOSD patients is primarily due to increased secretion in the liver and spleen in patients with AOSD [22, 31]. In a case report, Motoo et al. demonstrated that the increased serum LDH during AOSD flare-up was mainly of liver origin (LDH isoenzymes 4 and 5) [30]. CRP is produced only by hepatocytes, predominantly induced by IL-6, in response to inflammation [33]. However, its increase in serum could be dampened by severe liver dysfunction [34]. In contrast, the increase in serum level of IL-18 or ferritin could reflect the status of liver injury [1, 35–37]. The expression level of IL-37 is low in healthy human tissues but is stimulated in severe inflammatory conditions to inhibit excessive immune response [9, 21]. The serum level of IL-37 was elevated and correlated with disease activity markers in patients with various autoimmune diseases in previous studies [8–14, 21]. In all relevant previous studies regarding correlations between serum level of IL-18 and other serologic markers in patients with active AOSD, serum IL-18 level positively correlated with serum ferritin level and systemic disease scores of AOSD, similar to our study results [7, 17, 22, 24–26]. However, its correlations with serum ESR or CRP have shown inconsistent results, probably due to the different characteristics of patients studied [7, 17, 22, 25, 26]. Only two studies conducted by Priori et al. showed significant positive correlations between serum IL-18 level and non-specific inflammatory markers. However, unlike ours, their analyses included patients in inactive disease status of AOSD [7, 25]. According to a previous study of IL-37 in patients with AOSD conducted by Chi et al., serum IL-37 level positively correlated with non-specific disease activity markers including leukocytes and CRP but not with liver enzymes. However, unlike our study results, serum IL-37 level correlated well with IL-18 level in 62 patients with AOSD, one-third of whom were in inactive disease status of AOSD [8]. Our study findings are the first to demonstrate that IL-37 and IL-18 serum levels show different patterns of increase in

patients with high disease activity status of AOSD. In addition, taken together with previous study results, our results indicate that the pathogenic role of IL-37 for activity of AOSD is different from that of IL-18. Analyzing those two cytokines with different characteristics would be helpful for understanding this heterogeneous, multi-systemic disease.

Our study has several limitations. First, the sample size of this study was small owing to the rarity of the disease. However, our study was the largest comparing paired serum samples of both high and low disease activity status of AOSD. Second, our evaluation did not include other potential mechanistic cytokines of AOSD, such as IL-1 $\beta$ , IL-6, or TNF- $\alpha$  [8, 26]. Future studies with larger sample sizes that evaluate various serologic cytokine profiles are needed. Third, as our study was a retrospective observational study, patient visit interval or therapeutic protocol was not constant among patients. Study patients were treated by a single rheumatologist for the purpose of controlling disease activity with optimal medical therapies available. The patient visit interval was determined by clinical situation and varied from 2 weeks to 3 months during the observation period. Last, there was no consensus in defining high or low disease activity status of AOSD or in defining re-flare of disease after achieving low disease activity status. Therefore, we referred to previous studies that applied similar definitions [5, 7, 17]. However, we applied the operational definition of disease re-flare as increase in mPouchot score, increase in dosage or addition of immune modulating drugs including glucocorticoids.

In conclusion, we identified both serum IL-37 and IL-18 levels as useful disease activity markers in monitoring patients with AOSD. Each reflects different features of the disease.

## Abbreviations

IL: Interleukin; AOSD: adult-onset Still's disease; mPouchot: modified Pouchot; CRP: C-reactive protein; TNF: tumor necrosis factor; IFN: interferon; RA: rheumatoid arthritis; AS: ankylosing spondylitis; SLE: systemic lupus erythematosus; WBC: white blood cell count; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine aminotransferase

## Declarations

### Author's contributions

SN: study concept and design; acquisition of data; analysis and interpretation of data; methodology; drafting of the manuscript. SK: acquisition of data and critical review. JL: analysis and interpretation of data; methodology. DY: study concept and design; methodology; critical review; supervision. All authors read and approved the final manuscript.

### Funding

No specific funding was received from any bodies in the public, commercial, or not-for-profit sectors to carry out the work described in this article.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Ethics approval and consent to participate

The study protocol of current study was approved by the Institutional Review Board of Hanyang University Hospital, and informed consent was received from all participants (IRB no. HYUH 2016-06-007).

## Consent for publication

Each patient included in this study received written information and no patient objected to this study.

## Competing interest

The authors have declared no conflicts of interest


## References

1. Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. *Joint Bone Spine*. 2018;85:285-93.
2. Fautrel B. Adult-onset Still disease. *Best Pract Res Clin Rheumatol*. 2008;22:773-92.
3. Jung KH, Kim JJ, Lee JS, Park W, Kim TH, Jun JB, Yoo DH. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease. *Scand J Rheumatol*. 2014;43:162-9.
4. Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D, et al. Adult Still's disease: Manifestations, disease course, and outcome in 62 patients. *Medicine (Baltimore)*. 1991;70:118-36.
5. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. *J Rheumatol*. 2010;37:2369-76.
6. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. *Nat Rev Rheumatol*. 2018;14:603-18.
7. Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaianni G, Palazzo D, Valesini G. Interleukin 18: A biomarker for differential diagnosis between adult-onset Still's disease and sepsis. *J Rheumatol*. 2014;41:1118-23.
8. Shimizu T, Kikuchi-Taura A, Tsuji S, Matsushita M, Ohshima S, Saeki Y. Up-regulation of CD64 expression on monocytes in patients with active adult-onset Still disease: A possible biomarker of disease activity. *J Clin Rheumatol*. 2018; doi:10.1097/RHU.0000000000000931.
9. Xu WD, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases. *Autoimmun Rev*. 2015;14:1170-5.
10. Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. *PLoS One*. 2014;9:e95346.
11. Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, Yu T, Chen B, Zhang J, Ding L, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity. *J Transl Med*. 2014;12:69.
12. Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, Liu W, Li X. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. *J Clin Immunol*. 2013;33:111-7.
13. Chen B, Huang K, Ye L, Li Y, Zhang J, Zhang J, Fan X, Liu X, Li L, Sun J, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. *J Transl Med*. 2015;13:36.

14. Feng M, Kang M, He F, Xiao Z, Liu Z, Yao H, Wu J. Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients. *J Transl Med.* 2018;16:277.
15. Chi H, Liu D, Sun Y, Hu Q, Liu H, Cheng X, Ye J, Shi H, Yin Y, Liu M, et al. Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity. *Arthritis Res Ther.* 2018;20:54.
16. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol.* 1992;19:424-30.
17. Kim HA, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. *J Rheumatol.* 2012;39:1399-406.
18. van de Veerdonk FL, Netea MG. New Insights in the Immunobiology of IL-1 Family Members. *Front Immunol.* 2013;4:167.
19. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: Back to the future. *Immunity.* 2013;39:1003-18.
20. Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family—Balance between agonists and antagonists in inflammatory diseases. *Cytokine.* 2015;76:25-37.
21. Jia H, Liu J, Han B. Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases. *Biomed Res Int.* 2018;2018:3058640.
22. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. *Arthritis Rheum.* 2001;44:550-60.
23. Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. *Arthritis Rheum.* 2001;44:1716-7.
24. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. *J Rheumatol.* 2004;31:2189-98.
25. Priori R, Barone F, Alessandri C, Colafrancesco S, McInnes IB, Pitzalis C, Valesini G, Bombardieri M. Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis. *Rheumatology (Oxford).* 2011;50:776-80.
26. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS. Serum cytokine profiles in patients with adult onset Still's disease. *J Rheumatol.* 2003;30:2422-7.
27. Kudela H, Drynda S, Lux A, Horneff G, Kekow J. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. *BMC Rheumatol.* 2019;3:4.
28. Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. *Clin Immunol.* 2016;169:8-13.
29. Finotto S, Siebler J, Hausding M, Schipp M, Wirtz S, Klein S, Protschka M, Doganci A, Lehr HA, Trautwein C, et al. Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: A key role for IL-18 in regulating hepatocyte apoptosis in vivo. *Gut.* 2004;53:392-400.
30. Motoo Y, Ohta H, Okai T, Sawabu N. Adult-onset Still's disease: Hepatic involvement and various serum markers relating to the disease activity. *Jpn J Med.* 1991;30:247-50.

31. Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis—efficacy of interleukin-6 blockade and review of the literature. *Semin Arthritis Rheum*. 2011;40:365-8.
32. Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. *Immunol Rev*. 2000;174:192-209.
33. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. *J Clin Invest*. 2003;111:1805-12.
34. Pieri G, Agarwal B, Burroughs AK. C-reactive protein and bacterial infection in cirrhosis. *Ann Gastroenterol*. 2014;27:113-20.
35. Lim KB, Schiano TD. Still disease and the liver—an underappreciated association. *Gastroenterol Hepatol (N Y)*. 2011;7:844-6.
36. Slaats J, Ten Oever J, van de Veerdonk FL, Netea MG. IL-1beta/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections. *PLoS Pathog*. 2016;12:e1005973.
37. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE, Nash Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*. 2012;55:77-85.

## Figures



**Figure 1**

Scatter plot of IL-37 and IL-18 levels at high disease activity status of adult-onset Still's disease. IL interleukin. a Dotted lines represent the median values of IL-37 and IL-18.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryinformationver1.0.docx](#)